Exploring the Influence of Gastrointestinal Symptoms on Non-Motor Fluctuations in Parkinson’s Disease: Insights from the ReMePark-2, a Mexican Cohort
Objective: To determine the impact of gastrointestinal symptoms on NMF in PD among Mexican individuals living with PD (PwP). Background: The growing interest in the…Personality of Parkinson’s disease patients may influence the development and evolution of non-motor fluctuations
Objective: to evaluate the impact of personality on non-motor fluctuations (NMFs) in Parkinson’s disease (PD) and on NMFs evolution after dopaminergic treatments or deep brain…When Off Can Cost Life: Myocardial Infarction Due to Spontaneous Coronary Dissection as a Catastrophic Manifestation in Advanced Parkinson’s Disease.
Objective: Describe a patient with PD who suffered an acute myocardial infarction during a severe OFF period. Background: Advanced PD is characterized by complications including…Criteria Defining Chronic Pain Associated with Parkinson Disease
Objective: To assess the factors defining the association of chronic pain (>3 months) with PD. Background: Non-motor symptoms can be often associated with Parkinson disease…Uncovering Patient Perspectives on Parkinson’s Disease to Inform Individualized Care
Objective: To gather patient insights on the burden of Parkinson’s disease (PD), understand the level of patient involvement in treatment decision-making, and determine overall satisfaction…AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
Objective: This study developed a novel patient-independent, cost-effective AI model for detecting Freezing of Gait (FoG), using a single wearable sensor and without the need…A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler
Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…Clinical benefit of Opicapone in patients with different Parkinson disease phenopytes. The OPTIMO study
Objective: To assess the clinical benefit induced by opicapone (OPC) as an add-on therapy to levodopa in fluctuating Parkinson’s disease (PD) patients with special focus…Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of oral amantadine (AMA) compared to placebo in the treatment of dyskinesia (DYS) and motor fluctuations (MF) in…Characterising early morning akinesia and off (EMO) using Parkinson’s kinetigraph: analysis from a two centre national database in Parkinson’s disease .
Objective: Could wearable sensors such as Parkinson’s kinetograph (PKG) may provide valuable overnight data to detect EMO to augment care in clinic. Background: Early morning…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 26
- Next Page »